A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
What is oncology?
Oncology is the branch of medicine focused on cancer. Cancer itself is not a single disease. It is a family of more than 100 diseases, from breast cancer and lung cancer to blood cancers like leukemia and lymphoma. What they share is the same basic problem: cells that grow and divide without stopping. About 4 in 10 people in the US will be diagnosed with some form of cancer during their lifetime.
Cancer research moves faster than almost any other field of medicine. Cancer drugs made up about 35% of all new FDA drug approvals in 2025, 16 new medicines in one year. The 5 year survival rate for all cancers combined reached 70% for people diagnosed in 2015 to 2021, a first in US history. And survival for metastatic (spread) cancer has doubled since the mid 1990s, from 17% to 35%. Every one of those gains came through clinical trials.
Who can participate in oncology trials?
Every cancer trial sets its own rules, and in oncology they are usually specific. Most studies recruit around three things: your cancer type, your stage, and your treatment history. Many newer trials also require a biomarker, a specific mutation or protein found by testing your tumor, because modern cancer drugs often target one molecular change. Some trials enroll only newly diagnosed patients, others only people whose cancer has returned. Studies increasingly welcome older adults and people from communities that have been underrepresented in cancer research, because results need to reflect everyone who actually gets cancer. Eligibility always varies by study.
Do oncology trial participants get paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
Types of cancer clinical trials
Oncology clinical trials are designed to address different aspects of cancer care, including how to treat cancer, prevent it, find it early, or improve the quality of life for people with cancer. The main types are:
Treatment trials
Treatment trials test new treatments or new combinations of treatments, such as new drugs, new surgical techniques, or new radiation therapies. The goal is to find more effective ways to treat cancer with fewer side effects.
Prevention trials
Prevention trials look for better ways to prevent cancer in people who have never had cancer or to prevent cancer from returning. These trials may include studying medicines, vaccines, vitamins, minerals, or lifestyle changes.
Screening trials
Screening trials test the best way to detect cancer, especially in its early stages. These trials study new examinations or tests that might be more effective, safer, or less invasive than the current standard screening methods.
Quality of life trials for cancer survivors
Quality of life trials (or supportive care trials) explore ways to improve comfort and the quality of life for individuals with advanced cancer and cancer survivors. They may study issues such as managing side effects of treatment, physical, psychological, and social side effects of cancer and its treatment.
The stages of cancer, and why they matter for trials
Most solid tumors are described with a stage from 0 to IV, based on the TNM system: how large the tumor is (T), whether lymph nodes are involved (N), and whether it has spread, or metastasized (M):
- Stage 0. Abnormal cells are present but have not spread anywhere. Often called carcinoma in situ.
- Stage I. A small tumor that has not grown deeply or spread.
- Stage II and III. Larger tumors, or cancer that has reached nearby tissue or lymph nodes.
- Stage IV. Cancer has spread to distant parts of the body. Also called metastatic cancer.
Blood cancers like leukemia use different systems, since there is no single tumor to measure. The practical point for trial seekers: almost every cancer study names the stage it enrolls, right in the title ("locally advanced," "metastatic," "resectable"). Knowing your stage tells you at a glance which studies fit you. Many of the most active research areas, including immunotherapy and targeted therapy, run trials built specifically for stage IV patients.
How to enroll in a clinical trial for cancer
Enrolling in a cancer clinical trial through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to your cancer type. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore Study Details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the Health Profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.